• AG-126: ERK1/2 Assays in Striatal Models

  2026-09-09

  AG-126 (Tyrphostin AG-126) provides a practical pharmacology tool for testing ERK1/2 phosphorylation and cytokine-linked signaling in cellular assays. This guide connects established inflammatory-model evidence with a carefully bounded strategy for studying ERK pathway involvement in Neuroligin 1–D2-MSN research.

• Iron Stress Reprograms Enterocyte Metabolism

  2026-09-09

  Navazesh and Ji show that both iron deficiency and iron excess remodel metabolism and inflammatory gene expression in IPEC-J2 enterocytes, but through distinct patterns of transcriptional and metabolic change. The study’s combined iron perturbation, LPS challenge, and untargeted metabolomics design provides a useful framework for linking cellular iron status to intestinal proliferation, energy production, and epithelial resilience.

• FCCP Workflows for Mitochondrial Research

  2026-09-08

  Use FCCP to connect mitochondrial respiration, ATP production, hypoxia signaling, and organelle quality control in one experimentally controlled workflow. This guide pairs practical dosing and troubleshooting with the MARCH5–PEX3 findings that sharpen interpretation in mitochondrial biology research.

• BIBR 1532: A Translational Telomerase Strategy

  2026-09-07

  BIBR 1532 offers translational researchers a mechanistically distinct way to interrogate telomerase dependence, linking hTERT inhibition with telomere attrition, transcriptional control, cancer cell proliferation inhibition, and apoptosis. This article positions the compound alongside emerging telomere-damaging strategies and provides a practical framework for combining enzyme, molecular, and phenotypic readouts.

• Fenipentol Workflows for GI Research

  2026-09-07

  Fenipentol offers a practical small-molecule entry point for pancreatobiliary secretion, intestinal physiology, and mechanism-focused assay development. This guide distinguishes Fenipentol from the related isomer studied in hepatic stellate cells while translating that paper’s experimental logic into reproducible workflows.

• Ibrutinib (PCI-32765) BTK Research Workflow

  2026-09-05

  Build more reproducible B-cell signaling, viability, and washout experiments with Ibrutinib (PCI-32765), an irreversible BTK inhibitor designed for mechanistic research. This guide also shows how the ATRX-deficient glioma literature can inform assay stratification without overstating evidence for a BTK application.

• Pitavastatin (NK-104) In Vitro Workflow Guide

  2026-09-05

  Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase perturbation for cell-based and biochemical studies of cholesterol biosynthesis. This dossier-based guide covers formulation, controls, QC, and interpretation boundaries; it is not a protocol for clinical treatment, animal dosing, or unvalidated in vivo use.

• Fingolimod (FTY720) Assay Guide

  2026-09-04

  A practical, scenario-based guide to using Fingolimod (FTY720), SKU A8548, in viability, proliferation, cytotoxicity, and immune-trafficking studies. It connects receptor-level pharmacology with stock preparation, dose selection, controls, interpretation, and evidence-based product evaluation.

• Synthetic Receptor Microglia for Alzheimer’s Therapy

  2026-09-04

  Shao and colleagues engineered microglia with a synthetic efferocytic receptor that promotes amyloid-β clearance while limiting inflammatory activation. Their mRNA lipid nanoparticle strategy reprogrammed microglia in situ in mice and was associated with reduced amyloid burden, synapse elimination, and disease-related behavioral impairment.

• TMRE (C8197) for Mitochondrial Membrane Potential

  2026-09-03

  Tetramethylrhodamine ethyl ester perchlorate enables sensitive live-cell assessment of mitochondrial membrane potential. This guide explains how to use TMRE as a mechanistic readout in toxin-stress experiments, distinguish depolarization from mitochondrial ROS, and design more informative mitochondrial dysfunction studies.

• Cy3-UTP for Fluorescent RNA Workflows

  2026-09-02

  Cy3-UTP enables direct, bright labeling of newly transcribed RNA for imaging, binding assays, and nanoparticle-tracking workflows. This guide connects practical in vitro transcription RNA labeling with formulation studies, including controls, optimization ranges, and troubleshooting decisions.

• PCI-32765: Ibrutinib BTK Research Workflows

  2026-09-02

  Build reproducible BTK inhibition assays with Ibrutinib (PCI-32765), from B-cell receptor stimulation and chronic lymphocytic leukemia research to mechanism-focused viability workflows. The guide also explains how ATRX-stratified drug-screening principles from glioma research can improve experimental design without overstating evidence for BTK inhibition outside B-cell systems.

• Candidozyma auris in Guangzhou: Resistance and Virulence

  2026-09-02

  This Guangzhou study integrates whole genome sequencing, antifungal susceptibility testing, virulence phenotyping, biofilm analysis, and a Galleria mellonella infection model to distinguish two prevalent Candidozyma auris clades. Its findings connect clade-specific genetic patterns with fluconazole resistance, amphotericin B susceptibility differences, secreted aspartyl protease activity, biofilm formation, and experimental pathogenicity, providing a regional framework for surveillance and infection-control research.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-09-01

  The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, linking its inhibition to reduced renal fibrosis, inflammation, and epithelial-to-mesenchymal transition. Its combined inhibitor and tubular epithelial-cell design provides a useful framework for separating SMYD2-associated signaling from broader consequences of kidney injury.

• ASCH Proteins and N4-Acetylcytidine Processing

  2026-08-31

  Meng et al. define how the ASCH-domain enzyme EcYqfB hydrolyzes free N4-acetylcytidine to cytidine while showing that it does not remove ac4C from cellular RNA. Comparative structures of EcYqfB, mouse EOLA1, and the human TRIP4-ASCH domain reveal how related proteins can differ in substrate recognition, informing RNA modification and nucleotide-processing studies.

8400 records 1/560 page Next 12345 下5页 Last page